Novo Nordisk's shares saw an uptick following the FDA's approval of Wegovy, its flagship drug, to treat a severe fatty liver disease.

On Saturday, the U.S. Food and Drug Administration (FDA) approved an additional indication for Novo Nordisk A/S’ (NYSE:NVO) ...

Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated ...

Shares in Novo Nordisk rose as much as 5% in early European trading Monday, regaining some ground after losing more than half of their value over the past year.

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...

Copenhagen-listed shares in pharmaceuticals giant Novo Nordisk rose nearly 4% on Monday morning, after the company announced ...

The firm was granted U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis in adults with ...

Novo Nordisk shares (DK:NOVO.B) (NVO) rose 4% in Copenhagen trade. The stock however has plunged 46% this year amid increased competition for its weight-loss drugs as well as turmoil at the company.

Wegovy becomes the first GLP-1 based therapy authorized for MASH, which affects roughly 5% of U.S. adults, according to the ...

Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver ...

The Emmy-nominated Tramell Tillman immediately blew his whistle, with the band striking up the Powerman 5000 song “Relax,” ...